Cassava Sciences Inc. (NASDAQ:SAVA) received a formal letter from the U.S. Food and Drug Administration (FDA) related to the company’s trial for simufilamFollowing previously reported communications with the FDA regarding Cassava’s investigational new drug application and proposed proof-of-concept clinical trial for simufilam in tuberous sclerosis complex (TSC)-related epilepsy, the company confirmed a full FDA clinical hold.The SEC filing highlighted that the company has to provide the FDA with additional ...

Let's continue the conversation right here with Toron Slack. He's chief economist at Apollo Global Management. Um, you have a favorite in that Fed race, by the way.Well, so I don't have a personal favorite, but I think it's clear that the market is trying to chew hard on which of these candidates will have implications for what's happening, especially of course in rates. What the conclusion of course here is that it all becomes about can the new fetcher persuade the other FOMC members about whatever his vie ...

EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersFXEmpire is owned and operated by Empire Media Network LTD., Company Registration Number 514641786, registered at 7 Jabotinsky Road, Ramat Gan 5252007, Israel. The content provided on this website includes general news and publications, our personal analysis and opinions, and materials provided by third parties. This content is intended for educational and research purposes only. It does not constitute, and should not be interpreted a ...

Aspo Plc ANNOUNCEMENT 19.12.2025 Aspo Plc: Share repurchase 19.12.2025 In the Helsinki Stock Exchange Trade date 19.12.2025 Bourse trade Buy Share ASPO Amount 3 000SharesAverage price/ share 6,5067EURTotal cost 19 520,10EUR Aspo Plc now holds ...

We're back on Morning Trade Live. So, let's focus on Nike right now. The stock is selling off today after issuing a very gloomy outlaw.For more on that in a second, today's move on the chart is just the latest in a very up and down year. 6 months ago, the stock gapped up 15% after earnings and was trading as high as 80 bucks in late August, but since Labor Day, the stock is down more than 25%. And that is after today's slide.So, we are down right now. We're at 59 in change. Let's take a look at other athlei ...

The Alerian MLP ETF (NYSEARCA:AMLP) offers retirees an 8.75% dividend yield by investing in master limited partnerships that own energy infrastructure assets like pipelines, storage facilities, and processing plants. ...

Palantir (PLTR) has been riding the AI boom front and center for the last couple of years now, and outspoken CEO Alex Karp has been promising to defy legacy skepticism and reward true believers with epic financial results every step of the way. Karp’s holiday message in 2024 was incredibly bold to say the least. He thanked all the bulls who shunned Wall Street’s “rusty, crusty platitudes.” No slide deck, and no numbers. Karp just made a clear point about belief over consensus, and vision over noise. Mor ...

Gold prices are broadly flat in afternoon trading but set to close the week in positive territory."Persistent demand continues to underpin prices, with ongoing purchases by central banks and resilient ETF inflows," says Milad Azar of XTB MENA, while "geopolitical tensions remain a key supportive pillar."The latest U.S. inflation data came in below expectations, sparking a rally on Wall Street Thursday, but economists cautioned against reading too much into the report because of gaps in data collection durin ...

Second, global EV competition has intensified significantly. Tesla stock (NASDAQ: TSLA) came under pressure on Friday, plunging over 1% after volatility spread through the broader artificial intelligence space. The stock has alternated between gains and losses this week, with investors reassessing growth expectations amid competition from global rivals and execution risks around robotaxi deployment. Tesla's volatile trading reflects the market's struggle to price in the company's ambitious autonomous vehicl ...

PresentationThank you for standing by. My name is Jayel, and I will be your conference operator today. At this time, I would like to welcome everyone to the BioMarin business update. [Operator Instructions] I would now like to turn the conference over to Traci McCarthy, Head of Investor Relations. You may begin. Perhaps, your line is on mute, Traci.Traci McCartyGroup Vice President Thank you, Jayel, and good morning, everyone. Thank you for joining us to discuss BioMarin's acquisition of Amicus Therapeutics ...